Clinical trial / 2004
Oral resveratrol was well absorbed in humans but showed very low systemic bioavailability due to rapid metabolism.
Researchers examined the absorption, bioavailability, and metabolism of 14C-resveratrol following oral (25 mg) and intravenous doses in six human volunteers. Absorption of the oral dose was at least 70%, yielding peak plasma levels of resveratrol and metabolites of 491 +/- 90 ng/ml (about 2 microM) with a plasma half-life of 9.2 +/- 0.6 h. However, only trace amounts of unchanged resveratrol (<5 ng/ml) were detected in plasma. Most of the oral dose was recovered in urine as sulfate conjugates, glucuronic acid conjugates, and hydrogenated metabolites.
- Study type
- Pharmacokinetic trial
- Who was studied
- 6 human volunteers
- What was measured
- Absorption, bioavailability, and metabolism of 14C-resveratrol
THE PAPER
High absorption but very low bioavailability of oral resveratrol in humans.
Walle T, Hsieh F, DeLegge MH, Oatis JE, Walle UK. Drug Metab Dispos, 2004.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.